Business context and reporting period
Entity mismatch: Although the request identifies Celularity Inc., the supplied Form 10-Q is for GX Acquisition Corp., a Delaware blank-check company—not Celularity. It covers the quarter ended June 30, 2020, and was signed August 12, 2020. GX had not begun operating or generating revenue; its purpose was to pursue a business combination. The filing does not identify a target company.
Financial results and position
- Revenue: None. The company reported no operating revenue; income primarily reflected interest earned on trust assets.
- Quarterly results: Q2 2020 net loss was $143,588, versus net income of $634,660 in Q2 2019. Q2 operating costs were $208,233, up from $115,250. Interest income was $497,975, and an unrealized trust-investment loss was $471,500; the quarter also included a $38,170 tax benefit.
- Six-month results: Net income was $881,099 versus $634,539 in 2019. Operating costs were $449,872 versus $115,371; trust interest income was $1,607,050, while unrealized investment loss was $41,610. Basic and diluted net loss per common share, after allocating earnings to redeemable shares, was $0.03 for the six months, versus approximately $0.00 in 2019.
- Cash flow: Six-month operating cash outflow was $774,010. A $573,703 withdrawal from the trust account for taxes resulted in a $200,307 net decrease in cash; ending cash outside the trust was $716,700.
- Liquidity and assets: At June 30, cash outside the trust was $716,700, working capital was $786,624, and trust securities totaled $291,586,277. Total assets were $292,409,964; total liabilities were $10,965,109, including a $10,812,500 deferred underwriting fee payable. No long-term debt was reported. The trust held U.S. Treasury securities.
- Margins: Not applicable to this pre-combination SPAC, which had no operating revenue.
Material changes versus prior comparable period
Q2 results shifted from net income to a net loss, with higher operating costs and an unrealized trust-investment loss replacing the prior-year unrealized gain. For the first half, net income increased, but operating cash use rose from $194,810 to $774,010. Trust assets increased from $290,594,540 at December 31, 2019 to $291,586,277 at June 30, 2020.
Outlook, risks and unusual items
- GX had until May 23, 2021 to complete a business combination; otherwise it would have to cease operations and redeem public shares, subject to applicable requirements. Public shareholders could receive less than $10 per share, including if trust investments earned negative interest.
- Management said additional financing might be needed for working capital and transaction costs. Sponsor, officers and directors could lend funds but were not obligated to do so. The filing said these conditions raised substantial doubt about the company’s ability to continue as a going concern through the deadline if no combination was completed.
- The $10.8 million deferred underwriting fee was payable only if a business combination closed. Sponsor indemnification for certain trust-account claims was disclosed, but the company had not verified the sponsor’s ability to meet that obligation.
- Management reported disclosure controls were effective and no material change in internal control during the quarter. No legal proceedings or subsequent events requiring disclosure were reported.
Important facts for investors to verify
- Confirm the intended filing: this is GX Acquisition Corp.’s 10-Q, not a Celularity Inc. filing.
- Check the status and terms of any business combination, including whether a target was identified after the reporting date; none is named in this filing.
- Assess the company’s ability to fund pre-combination expenses and the going-concern warning, alongside the May 23, 2021 deadline.
- Review trust-account value, redemption terms, deferred underwriting fees, and the sponsor’s capacity to honor its indemnity.
- Distinguish consolidated net income from per-share results: redeemable shares’ allocation of trust earnings contributed to reported net loss per common share.